Filter by content type
Filter by year
Pepinemab – Anti-SEMA4D Antibody Treatment for Huntington’s Disease
CTAD 2021 presentation: SEMA4D blocking antibody, pepinemab , is a novel potential treatment for neurodegenerative disease: clinical proof of concept in HD supports clinical development in AD
SITC 2021 poster: Phase 1/2 study to evaluate pepinemab in combination with pembrolizumab in advanced, recurrent or metastatic head and neck cancer (KEYNOTE B84)
Pagination
- Previous page
- Page 2
- Next page